Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 7,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 7,000 shares of the company’s stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $19.39, for a total transaction of $135,730.00. Following the completion of the sale, the insider owned 933,188 shares in the company, valued at approximately $18,094,515.32. This trade represents a 0.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $19.19 on Wednesday. The stock has a market cap of $1.14 billion, a PE ratio of -9.60 and a beta of 0.89. The firm’s 50-day simple moving average is $20.00 and its two-hundred day simple moving average is $19.63. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. HC Wainwright increased their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, July 2nd. Robert W. Baird raised their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, June 16th. Finally, The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a “buy” rating and a $37.00 price target for the company. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $41.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. GAMMA Investing LLC grew its position in Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after acquiring an additional 2,630 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Enliven Therapeutics in the 1st quarter worth approximately $60,000. BNP Paribas Financial Markets boosted its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Tower Research Capital LLC TRC raised its holdings in Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares during the period. Finally, KLP Kapitalforvaltning AS boosted its stake in Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after buying an additional 2,500 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.